DuPont Genetics LLC

dupontgenetics.com

DuPont Genetics Rooted in the Northeast in early 2012. Pioneering the cannabis industry at the forefront ever since.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

BEIGENE ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH INNORNA TO JOINTLY DISCOVER NOVEL MRNA THERAPIES

InnoRNA and BeiGene | July 07, 2022

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics. “As a global biotec...

Read More

CELL AND GENE THERAPY

CTA APPROVAL OF BIOINVENT'S BI-1808, A FIRST-IN-CLASS ANTI-TNFR2 ANTIBODY, SETS STAGE FOR PHASE I/IIA TRIAL

BioInvent | October 27, 2020

news image

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has received regulatory authority approval of its clinical trial application (CTA) in Denmark for a Phase I/IIa, first-in-human study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)...

Read More

CELL AND GENE THERAPY

SPHERE FLUIDICS CLOSES A $40 MILLION FUNDING ROUND LED BY SOFINNOVA PARTNERS AND REDMILE GROUP

Sphere Fluidics | October 29, 2021

news image

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million investment round. The round was led by Sofinnova Partner and Redmile Group investing on equal terms. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers. Furthermore...

Read More

CELL AND GENE THERAPY

BROOKLYN IMMUNOTHERAPEUTICS ADDED TO ICE BIOTECHNOLOGY INDEX

Brooklyn ImmunoTherapeutics, Inc. | December 18, 2021

news image

Brooklyn ImmunoTherapeutics, Inc. on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announces that Brooklyn has been added to the ICE Biotechnology Index following the December 20, 2021 reconstitution. “The continued recognition of Brooklyn among key biotechnology indices is encouraging and we continue to believe that our value proposition and approach to...

Read More
news image

INDUSTRIAL IMPACT

BEIGENE ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH INNORNA TO JOINTLY DISCOVER NOVEL MRNA THERAPIES

InnoRNA and BeiGene | July 07, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics. “As a global biotec...

Read More
news image

CELL AND GENE THERAPY

CTA APPROVAL OF BIOINVENT'S BI-1808, A FIRST-IN-CLASS ANTI-TNFR2 ANTIBODY, SETS STAGE FOR PHASE I/IIA TRIAL

BioInvent | October 27, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has received regulatory authority approval of its clinical trial application (CTA) in Denmark for a Phase I/IIa, first-in-human study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL)...

Read More
news image

CELL AND GENE THERAPY

SPHERE FLUIDICS CLOSES A $40 MILLION FUNDING ROUND LED BY SOFINNOVA PARTNERS AND REDMILE GROUP

Sphere Fluidics | October 29, 2021

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million investment round. The round was led by Sofinnova Partner and Redmile Group investing on equal terms. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers. Furthermore...

Read More
news image

CELL AND GENE THERAPY

BROOKLYN IMMUNOTHERAPEUTICS ADDED TO ICE BIOTECHNOLOGY INDEX

Brooklyn ImmunoTherapeutics, Inc. | December 18, 2021

Brooklyn ImmunoTherapeutics, Inc. on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announces that Brooklyn has been added to the ICE Biotechnology Index following the December 20, 2021 reconstitution. “The continued recognition of Brooklyn among key biotechnology indices is encouraging and we continue to believe that our value proposition and approach to...

Read More